Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy

被引：0
|
作者：
Blackwell, K. L.
Burstein, H. J.
Sledge, G. W.
Stein, S.
Ellis, C.
Casey, M.
Baselga, J.
O'Shaughnessy, J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
[4] GlaxoSmithKline Inc, Collegeville, PA USA
[5] Vall Hebron Univ Hosp, Barcelona, Spain
[6] US Oncol, Dallas, TX USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：499S / 499S
页数：1
相关论文
共 50 条
  • [1] A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+metastatic breast cancer progressing on trastuzumab therapy
    O'Shaughnessy, J.
    Blackwell, K. L.
    Burstein, H.
    Storniolo, A. M.
    Sledge, G.
    Baselga, J.
    Koehler, M.
    Laabs, S.
    Florance, A.
    Roychowdhury, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
    Blackwell, Kimberly L.
    Burstein, Harold J.
    Storniolo, Anna Maria
    Rugo, Hope
    Sledge, George
    Koehler, Maria
    Ellis, Catherine
    Casey, Michelle
    Vukelja, Svetislava
    Bischoff, Joachim
    Baselga, Jose
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1124 - 1130
  • [3] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
  • [4] Lapatinib and trastuzumab combination shrinks HER2-positive cancer
    Coles, Charlotte
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (04) : 206 - 206
  • [5] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Carlos Acevedo-Gadea
    Christos Hatzis
    Gina Chung
    Neal Fishbach
    Kimberly Lezon-Geyda
    Daniel Zelterman
    Michael P. DiGiovanna
    Lyndsay Harris
    Maysa M. Abu-Khalaf
    Breast Cancer Research and Treatment, 2015, 150 : 157 - 167
  • [8] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Acevedo-Gadea, Carlos
    Hatzis, Christos
    Chung, Gina
    Fishbach, Neal
    Lezon-Geyda, Kimberly
    Zelterman, Daniel
    DiGiovanna, Michael P.
    Harris, Lyndsay
    Abu-Khalaf, Maysa M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 157 - 167
  • [9] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] STUDY OF S-1/TRASTUZUMAB COMBINATION THERAPY FOR HER2-POSITIVE METASTATIC BREAST CANCER
    不详
    ANNALS OF ONCOLOGY, 2010, 21 : 64 - 64
12345